Atlas Trials

Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

Clinical trial NCT05536128 · RECRUITING

Trial details

NCT number
NCT05536128
Sponsor
Seoul National University Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Breast Cancer
Start date
2022-12-31
Primary completion
2025-12-31
Enrollment
64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.